Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $44,885 | 17 | 64.8% |
| Travel and Lodging | $22,877 | 11 | 33.0% |
| Food and Beverage | $1,525 | 17 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $36,509 | 11 | $0 (2023) |
| Apellis Pharmaceuticals, Inc. | $13,357 | 12 | $0 (2023) |
| BioCryst Pharmaceuticals, Inc. | $8,713 | 9 | $0 (2021) |
| Genentech, Inc. | $7,425 | 2 | $0 (2022) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,025 | 1 | $0 (2023) |
| Mitsubishi Tanabe Pharma Development America, Inc. | $1,188 | 8 | $0 (2018) |
| Alnylam Pharmaceuticals Inc. | $69.70 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $15,925 | 12 | Apellis Pharmaceuticals, Inc. ($13,187) |
| 2022 | $4,130 | 3 | Genentech, Inc. ($3,960) |
| 2021 | $6,265 | 4 | Genentech, Inc. ($3,465) |
| 2020 | $26,761 | 10 | F. Hoffmann-La Roche AG ($21,511) |
| 2019 | $733.00 | 4 | BioCryst Pharmaceuticals, Inc. ($713.42) |
| 2018 | $15,473 | 12 | F. Hoffmann-La Roche AG ($14,285) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2023 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $96.08 | General |
| 08/04/2023 | Apellis Pharmaceuticals, Inc. | EMPAVELI (Drug) | Consulting Fee | Cash or cash equivalent | $11,869.00 | General |
| Category: Hematology | ||||||
| 06/23/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $82.37 | General |
| Category: Hematology | ||||||
| 06/23/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $67.80 | General |
| Category: Hematology | ||||||
| 06/23/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $61.10 | General |
| Category: Hematology | ||||||
| 06/23/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $53.50 | General |
| Category: Hematology | ||||||
| 06/23/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Travel and Lodging | Cash or cash equivalent | $22.98 | General |
| Category: Hematology | ||||||
| 06/22/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Travel and Lodging | Cash or cash equivalent | $628.80 | General |
| Category: Hematology | ||||||
| 06/22/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Travel and Lodging | Cash or cash equivalent | $215.46 | General |
| Category: Hematology | ||||||
| 05/09/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $712.80 | General |
| 03/04/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 03/01/2023 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $89.83 | General |
| Category: Hematology | ||||||
| 12/12/2022 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $125.19 | General |
| Category: Hematology | ||||||
| 07/18/2022 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | Cash or cash equivalent | $45.27 | General |
| Category: Hematology | ||||||
| 05/10/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,960.00 | General |
| 12/12/2021 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $50.12 | General |
| Category: Genetic Disease | ||||||
| 10/28/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,465.00 | General |
| 06/09/2021 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 03/01/2021 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 11/13/2020 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 09/29/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| Category: None | ||||||
| 09/14/2020 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 06/16/2020 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 05/05/2020 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 01/23/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $10,489.95 | General |
| Category: None | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 56 | 60 | $19,128 | $5,482 |
| 2022 | 3 | 71 | 80 | $24,180 | $7,002 |
| 2021 | 3 | 64 | 79 | $22,059 | $7,215 |
| 2020 | 3 | 50 | 64 | $17,835 | $4,846 |
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,639 | $1,890 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 26 | $6,088 | $1,804 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 17 | $5,400 | $1,789 | 33.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $10,334 | $2,735 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 38 | $8,395 | $2,331 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 18 | $5,451 | $1,935 | 35.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 33 | 45 | $9,765 | $3,038 | 31.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $7,320 | $2,328 | 31.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 17 | $4,974 | $1,848 | 37.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 21 | 32 | $9,363 | $2,620 | 28.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 13 | 13 | $4,349 | $1,238 | 28.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 19 | $4,123 | $988.91 | 24.0% |
About Dr. Charles Parker, M.D
Dr. Charles Parker, M.D is a Hematology & Oncology healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790735686.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Parker, M.D has received a total of $69,288 in payments from pharmaceutical and medical device companies, with $15,925 received in 2023. These payments were reported across 45 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($44,885).
As a Medicare-enrolled provider, Parker has provided services to 241 Medicare beneficiaries, totaling 283 services with total Medicare billing of $24,545. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology, Internal Medicine
- Location Salt Lake City, UT
- Active Since 05/11/2006
- Last Updated 11/10/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1790735686
Products in Payments
- Non-Covered Product (Drug) $35,796
- EMPAVELI (Drug) $11,869
- Empaveli (Drug) $1,392
- GIVLAARI (Drug) $50.12
- GIVLARRI (Drug) $19.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Salt Lake City
Daniel Couriel, M.d, M.D
Hematology & Oncology — Payments: $325,752
Shiven Patel, Md, Mba, Facp, MD, MBA, FACP
Hematology & Oncology — Payments: $148,156
Dr. Finn Petersen, M.d, M.D
Hematology & Oncology — Payments: $125,159
Dr. Heloisa Soares, M.d, M.D
Hematology & Oncology — Payments: $124,078
Deborah Stephens, D.o, D.O
Hematology & Oncology — Payments: $83,112
Dr. Xylina Gregg, M.d, M.D
Hematology & Oncology — Payments: $37,880